Clinically, it would be beneficial to explore FGFR3 inhibition together with the concurrent immune modulators, such as BCG, as a potential treatment strategy for FGFR3‐mutated or ‐overexpressing bladder cancer at an early stage. Here, FGFR3 is linked to urinary bladder cancer.